|
Index | - | P/E | - | EPS (ttm) | -3.05 | Insider Own | 6.47% | Shs Outstand | 3.53M | Perf Week | -13.46% |
Market Cap | 1.59M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | 3.30M | Perf Month | -39.02% |
Income | - | PEG | - | EPS next Q | - | Inst Own | 0.84% | Short Float / Ratio | 3.54% / 0.11 | Perf Quarter | -38.45% |
Sales | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Interest | 0.12M | Perf Half Y | -41.59% |
Book/sh | 0.86 | P/B | 0.52 | EPS next Y | - | ROA | - | Target Price | - | Perf Year | -88.40% |
Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | - | 52W Range | 0.47 - 5.00 | Perf YTD | -40.44% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -91.00% | Beta | - |
Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | -4.26% | ATR | 0.06 |
Employees | 3 | Current Ratio | - | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 23.65 | Volatility | 8.56% 9.28% |
Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.06 | Prev Close | 0.48 |
Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 1.06M | Price | 0.45 |
Recom | - | SMA20 | -24.71% | SMA50 | -41.75% | SMA200 | -57.67% | Volume | 63,667 | Change | -6.25% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. SciSparc Ltd. has collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite